Navigation Links
ActivBiotics Proposes Development Strategy for Its Novel Rifamycin Antibiotics
Date:2/25/2008

WELLESLEY HILLS, Mass., Feb. 25 /PRNewswire/ -- Joseph F. Finn, Jr., CPA, the Assignee for the Benefit of Creditors of ActivBiotics, as a result of growing interest from prospective buyers, announced today a development strategy for further advancement of the company's proprietary benzoxazinorifamycins as leading antibacterial drug candidates in combination antibiotic therapy. Rifalazil is the most developed of these compounds, though most of the interest for combination antibiotics has centered on novel compounds or new chemical entities ("NCEs").

Combination antibiotic therapy has been used as the treatment of choice for certain stubborn bacterial infections. Two prime examples are tuberculosis and gastric ulcer disease, caused by Mycobacterium tuberculosis infection and Helicobacter pylori infection, respectively. In both of these examples, the rifamycins rifampin and rifabutin have been used because of their potency against these pathogens. However, these rifamycins share the negative attribute of eliciting drug-drug interactions; that is, they interfere with the actions of many other medications that the patient may require. The NCEs are breakthrough drug candidates because they have not been shown preclinically to engender drug-drug interactions caused by the other rifamycins. In addition the NCEs have equal or superior potency compared with rifampin.

There is increasing recognition that rifamycins (e.g. rifampin and ABI- 0043) are highly efficacious against implant-associated staphylococcal infection. This property is due to their excellent efficacy against non- growing and surface-adhering staphylococci. No other class of antimicrobial agents shares this property. In view of the growing number of patients with implants (artificial joints, internal fixation devices, vascular grafts etc.) there is an urgent need for this type of antibiotic. "The development of an NCE for combination antibiotic treatment could be extremely beneficial," commented Werner Zimmerli, M.D., a leading infectious disease clinician and researcher at the University of Basel, Switzerland. "In our animal model for implant-associated infections, which has proven to be clinically predictive of combination antibiotic efficacy for the treatment of foreign body infections, the NCE ABI-0043 was as effective as rifampin. The fact that ABI-0043 is not predicted to have drug-drug interactions provides a very significant advantage over rifampin, which cannot be given, for example, in patients with oral anticoagulation due to dangerous interaction." In addition, based on their antibacterial spectrum and potency against key pathogens, the NCEs may also be developed for the treatment of bacterial endocarditis, osteomyelitis, acute and chronic respiratory infections, gastrointestinal infections, and acne.

The sale of ActivBiotics' assets, including rifalazil and the NCEs, is being conducted through an Assignment for the Benefit of Creditors. The bidding for the assets, which may be purchased separately or in combination, is scheduled for March 14, 2008.

For additional information on the terms of sale and to obtain a bidder's package, please contact Joseph F. Finn, Jr., CPA (jffinnjr@earthlink.net, phone 781-237-8840), Finn, Warnke & Gayton, 167 Worcester Street, Suite 201, Wellesley Hills, MA 02481-3613. For technical information on the assets, please contact Christo Shalish, cshalish@activbiotics.com.


'/>"/>
SOURCE ActivBiotics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ActivBiotics Outlines a Clinical Path Forward to Examine if Rifalazil Is Superior to Azithromycin in the Treatment of Chlamydia STD
2. ActivBiotics Receives Orphan Drug Designation from the European Medicines Agency for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis Indication
3. ActivBiotics to Present Results of Pivotal Study in the Treatment of Peripheral Arterial Disease at AHA Meeting
4. Cancer Cure Coalition Proposes Major Changes at the FDA
5. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
6. Immtech Focusing on Other Infectious Disease Programs Following Discontinuation of Development of Pafuramidine
7. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
8. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
9. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
10. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
11. Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... Las Piedras, Puerto Rico , where ... Following a comprehensive ... minor structural damage, temporary loss of power and minimal ... completed, manufacturing operations have resumed, and the company expects ...
(Date:10/10/2017)... EXTON, Pa. , Oct. 10, 2017   ... leader in innovative solutions for injectable drug administration, today ... of West,s ID Adapter for improving the intradermal administration ... the Fourth Skin Vaccination Summit in May 2017 by ... Team Lead, Polio Department, World Health Organization (WHO), and ...
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
Breaking Medicine Technology:
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... healthcare compliance program management, will showcase a range of technology and learning solutions ... Living (NCAL) Convention and Expo to be held October 14–18, 2017 at the ...
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... ... 2017 , ... Leading pediatric oncology experts at Children’s National Health System ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of ...
(Date:10/12/2017)... ... 2017 , ... Vohra Chief Medical Officer Dr. Shark Bird, ... nursing facility medical directors and other clinicians at various events in October. His ... many of these conferences we get to educate other physicians, facility nurses, corporate ...
Breaking Medicine News(10 mins):